Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two subpopulations were isolated on the basis of soybean agglutinin (SBA) binding, from the human Burkitt lymphoma line Daudi. The low- and high-binder sublines maintained this characteristic in continuous passages. Their surface marker profiles, antibodies, scanning electron microscope (SEM), cytochemical reactions and binding of other lectins (concanavalin A and wheatgerm agglutinin) were not different. They differed, however, in growth potential in athymic mice. The low-binder subline had lower frequency of takes, tumor weight and volume, and did not metastasize as compared to the high-binder subline. However, the reaction with F-SBA of all the tumor cells examined was strong (greater than 70%), indicating in vivo selection and tumor development of high binder cells.
 ...
PMID:Sublines of the Burkitt line Daudi, selected on the basis of reactivity with soybean agglutinin, differ in tumorigenicity in athymic mice. 316 47

The histological diagnosis of non-Hodgkin's lymphoma (Burkitt's lymphoma excluded) in 147 children was reviewed. The most common site of presentation was in the abdomen (32.6%). The most frequent site of metastatic disease at diagnosis was the bone marrow (27.2%). The most common histology was diffuse undifferentiated non-Burkitt type (37.4%). According to the Murphy staging system, 40.1% were stage III and 27.2% were stage IV. In a nonrandomized prospective study, 121 patients were submitted to a treatment regimen (protocol 8001) and compared with 26 historical controls treated with the COP regimen, consisting of cyclophosphamide, vincristine, and prednisone. Of those patients treated with protocol 8001, nine had intestinal perforation at the site of primary disease. All patients in this group were malnourished at the time of perforation. The overall rate of initial complete remission in those patients treated with protocol 8001 was 90.7%. The duration of remission was from 16 to 108 months, with a median of 39 months. The actuarial rate of disease-free survival was 69% at 2 years and 63% at 6 years, compared with 36% at 6 years of the control group (COP) (p less than 0.01). None of the patients have relapsed after 4 years.
 ...
PMID:Treatment of non-Hodgkin's lymphoma in Mexican children. The effectiveness of chemotherapy during malnutrition. 332 20

Radiation is curative in many types of localized cancer, whereas chemotherapy is rarely curative in either localized or widespread cancer. For this reason, chemotherapy should never be employed in any situation where it might hinder or prevent the administration of a potentially curative dose of radiation. However, in Burkitt's tumor in Africa, where a multicentric origin seems to be much more probable, cyclophosphamide, 40 mg/kg intravenously repeated every 3 to 4 weeks, has occasionally been curative. In the treatment of Wilms' tumor, surgery, radiation and chemotherapy are essential for optimal results. In acute leukemia, chemotherapy with the conventional agents, as well as newer drugs such as cytosine arabinoside and L-asparaginase, is the treatment of choice, with radiation being useful mainly in treatment of localized disease in the bones or in the central nervous system. The great interest in L-asparaginase at the present time lies in the fact that certain neoplastic cells have a specific nutritional requirement for the amino acid L-asparagine, whereas no normal cells appear to have this requirement. In many cases of advanced neoplastic disease, the partnership of radiation therapy to reduce large bulky lesions composed to a large extent of nonproliferating cells, followed by chemotherapy to destroy the few surviving and now perhaps proliferating cells remaining in the original mass or in metastases, would seem to offer the greatest promise of theoretical and practical benefit.
 ...
PMID:Chemotherapy and radiotherapy--competitors or partners? 437 33

The tremendous progress that has been made in the chemotherapy of malignant diseases since the early 1950's has enabled the cure of a significant number of cancers such as chloriocarcinoma, Burkitt's lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, the acute leukaemias, testicular carcinoma, and many childhood cancers such as rhabdomyosarcoma, Wilm's tumor, Ewing's sarcoma, ovarian cancer, and retinoblastoma. As a result, the mortality from cancers has dropped by 15% for persons under the age of 45 years and even more for those under 30 years of age. Many other metastatic cancers can now be successfully controlled with chemotherapy and, ultimately, more will be added to the growing list of curable cancers. The chemotherapeutic agents responsible for the cures of some cancers include asparaginase, actinomycin D, Adriamycin, bleomycin, cisplatin, cyclophosphamide, cytosine arabinoside, 5-fluorouracil, 6-mercaptopurine, methotrexate, nitrogen mustard, prednisone, procarbazine, and vincristine. The discovery of new effective drugs such as AMSA and anthracenedione promises to improve the success rates obtained with present therapy. Chemotherapy is indicated for every patient who has metastatic cancer, since virtually every patient can receive some palliation from such therapy, while for some patients chemotherapy holds the promise of prolongation of life or even cure.
 ...
PMID:The curability of advanced cancers with chemotherapy. 627 28

To evaluate the significance of karyotypic evolution of tumor cells with an 8;14 translocation [t(8;14)(q24;q32)], we examined the clinicopathologic features and immunologic phenotypes of nine Japanese patients with various types of B-cell malignancy with the translocation. All these patients had structural rearrangements of the long arm of chromosome No. I (Iq) in a stem line or the subline of tumor cells with a t(8;14). The rearrangements were composed of a translocation involving Iq with other chromosomes and a tandem duplication of Iq, and they were exclusively associated with a partial trisomy for Iq. Two patients with diffuse large-cell lymphoma, whose tumor cells did not express surface immunoglobulins (s-Ig), had the Iq translocation in their highly complex karyotypes. Tumor cells from the other seven patients expressed s-Ig and the karyotypes were relatively simple. Among these patients, the Iq translocation was found in two patients with Burkitt's lymphoma, and the Iq duplication were observed in a stem line or the sublines from four patients with Burkitt's lymphoma-leukemia and one each with small non-cleaved-cell or diffuse large-cell lymphoma. Except for one patient in the stage of IE, these patients had a poor prognosis because of the clinical conversion of extranodal metastases in the earlier disease phase. These findings are compatible with those of Western patients with a t(8;14). Therefore, tumor cells marked primarily with a t(8;14) could have "major routes" in the karyotypic evolution, for which potentials should be recognized as clinical risk factors, and the morphologic presentation and the expression of surface immunoglobulins may be associated with the process of karyotypic evolution.
 ...
PMID:Karyotype evolution in B-cell lymphoid malignancy with an 8;14 translocation. 660 42

Two cases of Burkitt's tumor treated in the Pediatric Hospital, Owendo, Libreville are discussed. The tumors were of the maxillofacial type, and remission by chemotherapy was obtained for a period of between 6 to 8 months. After this length of time, and in spite of spectacular local results, metastases developed and led to a fatal outcome. Cyclophosphamide chemotherapy is effective locally, but does not prevent recurrence.
 ...
PMID:[Malignant lymphoma or Burkitt's tumor. Apropos of 2 cases]. 685 Sep 51

Despite the fact that tumour cells with the potential for metastasis may circulate randomly, many demonstrate a preference for specific organs. Recently, several investigators have selected variant tumour cell lines with enhanced capacity to metastasize to specific organs, mainly using the spontaneously originating B16 melanoma cell line of the mouse and tumour variants with enhanced capacity to metastasize to the lungs, brain and liver. We previously reported the derivation of a liver-specific metastatic variant of a Marek's disease (MD) virus-transformed, non-producer lymphoma cell line. MD is a naturally occurring, herpes virus-induced, T-cell lymphoma of chickens which bears pathological and aetiological similarities to Burkitt's lymphoma in man. This makes MD a useful model for study. One similarity is the pattern of metastasis in which both lymphomas induce a high incidence of ovarian and liver lesions. We now report the existence of a cell-surface antigen, detectable by a monoclonal antibody, correlated with organ-specific metastasis.
 ...
PMID:Detection of a cell-surface antigen correlated with organ-specific metastasis. 740 15

Ultrasonography can be used to guide fine needle biopsy of suspected malignant liver lesions. In Abidjan this method allowed cytologic identification of 63 liver lesions disclosed by ultrasonography. In 53 cases (84%) including 41 hepatocarcinomas, 4 Burkitt's lymphomas, and 8 metastases, cytology confirmed malignancy. In 10 cases, initially supposed to be hepatocarcinomas (6 cases) or metastases (4 cases), cytologic findings led to a different diagnosis of either cirrhosis, abscess, or necrotic tissue (4 cases). No complications were observed in this series of 63 ultrasonically guided biopsies. This safe, easy, sensitive, and cost-effective technique should be used to identify the solid tumors. This indication is common in Black Africa where these tumors are common.
 ...
PMID:[Ultrasonically guided fine needle biopsy in the diagnosis of malignant liver tumors]. 876 93

Rhenium-188 (beta- = 2.2 MeV; gamma = 155 keV; T1/2 16.9 hours) is an attractive therapeutic radioisotope which is produced from decay of the reactor-produced tungsten-188 parent (T1/2 69 days) and thus conveniently obtained on demand by elution from the alumina-based tungsten-188 /rhenium-188 generator system. The rhenium-188 is obtained as sodium perrhenate by elution of the generator with 0.9% saline. The post elution use of disposable tandem, ion-exchange columns is a simple method for the concentration of rhenium-188 saline solutions with specific volumes > 500 mCi/ml. This method can also extend the useful shelf-life of the generator, which can be as long as one year. The long useful shelf-life of the generator is expected to provide rhenium-188 at very reasonable costs for routine preparation of a variety of radiopharmaceuticals for the treatment of a variety of cancers including breast cancer. We are evaluating two types of Re-188-labeled agents under investigation which have potential for the treatment of breast cancer. Rhenium-188-labeled hydroxyethylidenediphosphonate (HEDP) and Re-188-dimercaptosuccinic acid (DMSA) are being applied for palliative treatment of pain associated with skeletal metastases, and the Re-188-RC-160 somatostatin analogue [cyclic NH2-(D)-Phe-Cys-Try-(D)-Trp-Lys-Val-Cys-Trp-NH2] for somatostatin-receptor-positive tumors. The results of initial clinical studies with the two bone pain agents demonstrate good targeting to skeletal metastases, and use of Re-188-HEDP has resulted in pain palliation with minimal bone marrow suppression in the initial patient studies. While these initial studies have been conducted in patients with prostate cancer, similar results are expected in planned studies in breast cancer patients. In animal studies, Re-188-RC-160 has been successfully used for the local/regional treatment of experimental breast cancer and other cancers. Re-188-RC-160 binds to somatostatin-receptor-positive cells both in vitro and in vivo, including breast cancer cells (ZR-75-1 breast carcinoma and NCI-H69 human small cell ling carcinoma), but not to binding-negative cells (Raji, Burkitt's lymphoma). A structurally similar Re-188-cyclic peptide with different binding specificity (CTOP [cyclic NH2-(D)-Phe-Cys-Try-(D)-Trp-Orn-Thr-Pen-Thr-ol]; an opiate-receptor antagonist) did not bind to target cells. Both gentisic acid and ascorbic acid are present in the Re-188-HEDP and Re-188-RC-160 formulations, and have been found to also significantly reduce radiolytic degradation of the somatostatin peptide analogues, and may have general application in the stabilization of Re-188-labeled radio-pharmaceuticals.
 ...
PMID:Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. 917 35

From 1987 to 1995, 22 children with refractory solid tumors entered a phase II study of high-dose thiotepa (HDT) (900 mg/m2) followed by stem cell transplantation (SCT) in the Pediatrics Department of the Institut Gustave Roussy. Tumor types were rhabdomyosarcoma (eight), osteosarcoma (seven), neuroblastoma (three), Ewing's sarcoma (three) and Burkitt's lymphoma (one). Before HDT, all had been extensively treated with conventional chemotherapy, surgical resection of the primary tumor (13/22) and of metastases (6/22), and radiotherapy of the primary tumor in three patients. All had measurable disease, at the site of the primary tumor (3 patients), of the metastases (9 patients) or both (10 patients). Toxicity from the HDT was severe but acceptable. No toxicity-related death occurred. The median duration of neutropenia and thrombocytopenia was 18 days (5-37) and 30 days (7-377), respectively. Septicemia was documented in four patients. Severe diarrhea was observed in seven patients. Mild hepatic toxicity occurred 18 times. No CR and 11/22 PR were documented: osteosarcoma 4/7, rhabdomyosarcoma 4/8, Ewing's sarcoma 2/3; 1/1 Burkitt's lymphoma progressed. We conclude that at a dose of 900 mg/m2 followed by SCT support in these heavily pretreated children, the main toxicity induced by thiotepa was digestive. The response rate observed, especially in sarcoma, is particularly encouraging. Thiotepa should be further evaluated in HDC regimens either in combination with other alkylating agents or in rapidly cycled courses of HDC with SCT.
 ...
PMID:Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. 975 39


<< Previous 1 2 3 4 Next >>